reports
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Muco...
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden and improvement in lung infection BEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its oral formulation of the potent antifungal ...
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentat...
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024 MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Benjamin Bakall, MD, PhD, Director of Clinical Research at Associated Retina Consultants and Clinical Assistant Professor at the University of Arizona, College of Medicine—Phoenix will present data from the OCU400 Phas...
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Assoc...
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic ...
Ocugen to Present on Modifier Gene Therapy Platform at Association for...
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410 for the treatment of geographic atrophy (P...
Kinder Morgan Inc: 1 director
A director at Kinder Morgan Inc sold 230,000 shares at 18.820USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy...
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy MALVERN, Pa., April 19, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV-hRORA)—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced...
Kinder Morgan Reports First Quarter 2024 Financial Results
HOUSTON--(BUSINESS WIRE)-- Kinder Morgan, Inc.’s (NYSE: KMI) board of directors today approved a cash dividend of $0.2875 per share for the first quarter ($1.15 annualized), payable on May 15, 2024, to stockholders of record as of the close of business on April 30, 2024. This dividend is a 2% increase over the first quarter of 2023. The company is reporting: First quarter earnings per share (EPS) of $0.33 and distributable cash flow (DCF) per share of $0.64, up 10% and 5%, respectively, compared to the first quarter of 2023. Net income attributable to KMI of $746 million, compared to $...
Angi Inc. to Announce Q1 2024 Earnings on May 7th and Host Earnings Co...
Angi Inc. to Announce Q1 2024 Earnings on May 7th and Host Earnings Conference Call on May 8th DENVER, April 16, 2024 (GLOBE NEWSWIRE) -- After the close of market trading on Tuesday, May 7, 2024, Angi Inc. (NASDAQ: ANGI) will post its first quarter results at . On Wednesday May 8, 2024, at 8:30 a.m. ET, Angi Inc. and IAC will host a conference call to answer questions regarding the companies’ respective first quarter results. The live audiocast and replay will be open to the public through the investor relations section of the Angi site at . About Angi Inc. Angi (NASDAQ: ANGI) helps...
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual ...
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference, presented by Noble Capital Markets, taking place from A...
Kinder Morgan Announces First Quarter ‘24 Earnings Webcast
HOUSTON--(BUSINESS WIRE)-- Kinder Morgan, Inc. (NYSE: KMI) today announced it will release first quarter 2024 earnings results on Wednesday, April 17, 2024 after market close and will hold a live webcast and conference call. What: Kinder Morgan First Quarter ‘24 Earnings Results Webcast When: April 17, 2024, at 3:30 p.m. CT, 4:30 p.m. ET Where: How: Live over the Internet by logging on to the web at the above address, or by phone (listen-only) by dialing 1-517-308-9431 and entering the passcode 8305461. If you are unable to listen during the live webcast, the call will be archived a...
Ocugen, Inc. Announces Positive Scientific Advice from the European Me...
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication MALVERN, Pa., April 10, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) reviewed the study design, endpoints and planned stati...
Angi Appoints Jeff Kip as CEO
Angi Appoints Jeff Kip as CEO DENVER, April 08, 2024 (GLOBE NEWSWIRE) -- Angi (NASDAQ: ANGI), the leading and most comprehensive solution for all home care needs, today announced the appointment of Angi President and long-time IAC and Angi executive Jeff Kip to CEO, succeeding Joey Levin. As CEO, Mr. Kip will lead Angi’s executive team, overseeing strategy and daily management of the company. Mr. Levin, CEO of IAC, will continue as Chairman of the Angi Board of Directors. All changes are effective immediately. “Through multiple roles, Jeff Kip has been a student of the Angi business, fir...
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate...
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) amendment to initiate a Phase 3 clinical trial of OCU400, ...
AC Reports Preliminary March 31 Book Value of $42.67 to $42.87 Per Sha...
AC Reports Preliminary March 31 Book Value of $42.67 to $42.87 Per Share GREENWICH, Conn., April 05, 2024 (GLOBE NEWSWIRE) -- Associated Capital Group, Inc. (“AC” or the “Company”) (NYSE:AC), announced today a preliminary range for its first quarter book value of $42.67 to $42.87 per share. This compares to $42.11 per share at December 31, 2023 and $41.30 per share at March 31, 2023. AC will be issuing further details on its financial results in May. About Associated Capital Group, Inc.Associated Capital Group, Inc. (NYSE: AC), based in Greenwich, Connecticut, is a diversified global fi...
Ocugen Announces Positive Data and Safety Monitoring Board Review and ...
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy Established Low Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Approval to Proceed with Medium Dose Cohort Dosing Malvern, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Sa...
PennantPark Floating Rate Capital Ltd. Schedules Earnings Release of S...
PennantPark Floating Rate Capital Ltd. Schedules Earnings Release of Second Fiscal Quarter 2024 Results MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) (TASE:PFLT) announced that it will report results for the second fiscal quarter ended March 31, 2024 on Wednesday, May 8, 2024 after the close of the financial markets. The Company will also host a conference call at 9:00 a.m. (Eastern Time) on Thursday May 9, 2024 to discuss its financial results. All interested parties are welcome to participate. You can access the conferenc...
Matinas BioPharma Prices $10 Million Registered Direct Offering
Matinas BioPharma Prices $10 Million Registered Direct Offering BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, today announced it has entered into securities purchase agreements with healthcare-focused institutional investors for the purchase and sale of 33,333,334 shares of common stock, par value $0.0001 per share, and warrants to purch...
PennantPark Floating Rate Capital Ltd. Announces Monthly Distribution ...
PennantPark Floating Rate Capital Ltd. Announces Monthly Distribution of $0.1025 per Share MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- PennantPark Floating Rate Capital Ltd. (the "Company") (NYSE: PFLT) (TASE: PFLT) declares its monthly distribution for April 2024 of $0.1025 per share, payable on May 1, 2024 to stockholders of record as of April 15, 2024. The distribution is expected to be paid from taxable net investment income. The final specific tax characteristics of the distribution will be reported to stockholders on Form 1099 after the end of the calendar year and in the Company's pe...
Ocugen Provides Business Update with Certain Financials for the Year E...
Ocugen Provides Business Update with Certain Financials for the Year Ending 2023 Conference Call and Webcast Today at 8:30 a.m. ET Received alignment with FDA for broad retinitis pigmentosa (RP) indication in Phase 3 clinical trial of OCU400—first gene therapy program to receive a broad indication for RP. OCU400 Phase 3 clinical trial expected to commence in April 2024. Regenerative Medicine Advanced Therapy (RMAT) designation granted by FDA to OCU400 Completed Cohort 1 dosing for OCU410 and OCU410ST gene therapy clinical studies for geographic atrophy (GA) and Stargardt disease, respecti...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.